J&J Pauses COVID-19 Vaccine Candidate Clinical Trials Due to Unexplained Illness

News
Article

The unexplained illness in a study participant is being reviewed and evaluated by an independent data safety monitoring board and internal clinical and safety physicians.

On Oct. 12, 2020, Johnson & Johnson (J&J) announced that it is temporarily pausing clinical trials, including a Phase III trial (Ensemble), for its COVID-19 vaccine candidate because a study participant developed an unexplained illness.

Currently, the patient’s illness is being reviewed and evaluated by the Ensemble trial’s independent data dafety monitoring board as well as internal clinical and safety physicians, a company press release said.

“Adverse events—illnesses, accidents, etc.—even those that are serious, are an expected part of any clinical study, especially large studies,” J&J stated in the press release. “Based on our strong commitment to safety, all clinical studies conducted by the Janssen Pharmaceutical Companies of Johnson & Johnson have prespecified guidelines. These ensure our studies may be paused if an unexpected serious adverse event that might be related to a vaccine or study drug is reported, so there can be a careful review of all of the medical information before deciding whether to restart the study.”

Source: Johnson & Johnson

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content